Highlights Cyxone AB

Equities

CYXO

SE0007815428

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.104 ^SEK	+16.20%		+1.96%	+3.59%

May. 14	Cyxone AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 22	Sweden's Cyxone Appoints New CEO	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cyxone AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Cyxone Enters Research Deal for Rheumatoid Arthritis Therapy	Mar. 25	MT
Cyxone Enters Important Research Collaboration with University of Glasgow	Mar. 25	CI
Cyxone AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Cyxone Reaches an Important Milestone for the Drug Candidate Rabeximod	Jan. 15	CI
Cyxone AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-27	CI
Cyxone to Receive Unitary Patent in EU for T20K Drug Candidate	23-10-09	MT
Cyxone AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
Cyxone Revises Strategy for Commercial Alignment Targeting Valuable Market Opportunities	23-08-29	CI
EU to Grant Cyxone Divisional Patent for Multiple Sclerosis Drug Candidate	23-05-31	MT
Cyxone AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Sweden’s Cyxone Secures US Patent Approval for Rabeximod Compound	23-05-09	MT
Cyxone AB Receives Notice of Allowance from the US Patent Office for the Protection of Rabeximod Compounds	23-04-02	CI
Cyxone AB Makes Significant Progress in the Manufacturing Process for Rabeximod	23-03-09	CI
Cyxone AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-17	CI
Cyxone AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-17	CI
Cyxone Wins Georgian Nod for Phase 2b Study for Rheumatoid Arthritis Drug	23-02-09	MT
Cyxone AB Receives Ethical and Regulatory Approval from Georgia to Conduct Clinical Phase 2B Study in RA	23-02-09	CI
Cyxone Completes National Filings for Arthritis Drug Patents	23-02-06	MT
Cyxone AB Advances the Patent Portfolio for Rabeximod	23-02-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cyxone AB

Equities

CYXO

SE0007815428

Highlights

Filters